These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20225325)

  • 1. Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status.
    Shoushtari A; Meeneghan M; Sheng K; Moskaluk CA; Thomas CY; Reibel JF; Levine PA; Jameson MJ; Keene K; Read PW
    Cancer; 2010 Jun; 116(11):2645-54. PubMed ID: 20225325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
    Bar-Ad V; Wang ZX; Leiby B; Tuluc M
    J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.
    Shonka DC; Shoushtari AN; Thomas CY; Moskaluk C; Read PW; Reibel JF; Levine PA; Jameson MJ
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1126-32. PubMed ID: 19917926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal response after 46 Gy of intensity-modulated radiotherapy is associated with human papillomavirus-related oropharyngeal carcinoma.
    Dronkers EAC; Koljenovic S; Verduijn GM; Baatenburg de Jong RJ; Hardillo JAU
    Laryngoscope; 2018 Oct; 128(10):2333-2340. PubMed ID: 29521420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma.
    Motegi A; Fujii S; Zenda S; Arahira S; Tahara M; Hayashi R; Akimoto T
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):461-8. PubMed ID: 26867875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.
    Maquieira R; Haerle SK; Huber GF; Soltermann A; Haile SR; Stoeckli SJ; Broglie MA
    Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1841-8. PubMed ID: 26059208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
    Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
    Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity.
    Broglie MA; Soltermann A; Haile SR; Röösli C; Huber GF; Schmid S; Stoeckli SJ
    Laryngoscope; 2013 Jan; 123(1):164-70. PubMed ID: 23154864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive intensity-modulated radiotherapy concurrent with systemic therapy for oropharyngeal squamous cell carcinoma: Outcomes from an integrated regional Australian cancer centre.
    Masoud Rahbari R; Winkley L; Hill J; Tahir AR; McKay M; Last A; Shakespeare TP; Dwyer P
    J Med Imaging Radiat Oncol; 2016 Jun; 60(3):414-9. PubMed ID: 26786975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
    Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
    Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response evaluation of the neck in oropharyngeal cancer: Value of magnetic resonance imaging and influence of p16 in selecting patients for post-radiotherapy neck dissection.
    Lilja-Fischer JK; Jensen K; Eskildsen HW; Fink-Jensen V; Nielsen VE
    Acta Oncol; 2015; 54(9):1599-606. PubMed ID: 26198649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients.
    Verma V; Liu J; Eschen L; Danieley J; Spencer C; Lewis JS; Diaz J; Piccirillo JF; Adkins DR; Nussenbaum B; Thorstad WL; Gay HA
    Radiat Oncol; 2015 Jan; 10():8. PubMed ID: 25572866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
    Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
    Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
    Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of keratinization with 5-year disease-specific survival in oropharyngeal squamous cell carcinoma.
    Cooper T; Biron VL; Adam B; Klimowicz AC; Puttagunta L; Seikaly H
    JAMA Otolaryngol Head Neck Surg; 2015 Mar; 141(3):250-6. PubMed ID: 25554966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does elimination of planned postoperative radiation to the primary bed in p16-positive, transorally-resected oropharyngeal carcinoma associate with poorer outcomes?
    Sinha P; Pipkorn P; Thorstad WL; Gay HA; Haughey BH
    Oral Oncol; 2016 Oct; 61():127-34. PubMed ID: 27688115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
    Haughey BH; Sinha P
    Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective functional outcomes in sequential population based cohorts of stage III/ IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity modulated radiotherapy.
    Kerr P; Myers CL; Butler J; Alessa M; Lambert P; Cooke AL
    J Otolaryngol Head Neck Surg; 2015 May; 44(1):17. PubMed ID: 25964113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.